Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Pulmonary Embolism Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The pulmonary embolism market size has grown rapidly in recent years. It will grow from $1.81 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to anticoagulant therapies, research and clinical trials, pulmonary embolism awareness, vte prophylaxis.

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, health equity initiatives, global health initiatives. Major trends in the forecast period include artificial intelligence in diagnosis, novel anticoagulants, pulmonary embolism response teams, patient-centered care.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

Market Segmentation:
The main types of treatment for pulmonary embolism are medications, mechanical devices, surgery and others. Medications refer to substances used for medical treatment, management, prevention, or relief of various medical conditions and illnesses. It is diagnosed with various methods, such as a chest X-ray, electrocardiogram (ECG), magnetic resonance imaging (MRI), computed tomography scan, pulmonary angiography, venography, venous ultrasound, D-Dimer test and others. It has various symptoms such as shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis and others and its drugs are mainly distributed through hospital pharmacies, retail pharmacies, online pharmacies and others. The main end-users are hospitals, specialty clinics, homecare and others.

Major Driver - Rising Prevalence Of Blood Clots Fuels Growth In The Pulmonary Embolism Market
The increasing prevalence of blood clots is expected to propel the growth of the pulmonary embolism market going forward. A blood clot, also known as a thrombus, is a gel-like or semisolid mass that forms within a blood vessel. Blood clots raise the risk of pulmonary embolism by obstructing blood flow to the lungs. This blood clot causes blockage, typically in the legs' deep veins, thus increasing the risk of pulmonary embolism. For instance, in April 2022, according to an article published by Gavi, the Vaccine Alliance, an international organization created to improve access to new and underused vaccines for children, stated that in the 30 days following exposure to COVID-19, scientists discovered a 33-fold rise in the chance of potentially fatal clots in the lungs and a five-fold increase in the risk of deep vein thrombosis. Therefore, an increasing prevalence of blood clots is driving the growth of the pulmonary embolism market.

Competitive Landscape:
Major players in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Top Trend - Leading Companies In The Pulmonary Embolism Market Innovate With Advanced Catheter Solutions
Major companies operating in the pulmonary embolism market are focused on developing innovative products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter to gain a competitive advantage. For instance, in June 2023, Inari Medical Inc., a US-based medical device company, launched the Triever16 Curve catheter and the RevCore thrombectomy catheter. This innovative Triever16 Curve catheter is designed for peripheral thrombectomy and pulmonary embolism procedures. It is highly trackable and has a pre-shaped curve for focused aspiration. The catheter also features a unique design that allows easy access to larger and more powerful 20F or 24F catheters and the RevCore thrombectomy catheter is designed to treat venous in-stent thrombosis. It is a mechanical thrombectomy device that uses a nitinol basket to capture and remove blood clots. Moreover, these catheters also improve the safety and effectiveness of pulmonary embolism procedures.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Pulmonary Embolism Market Characteristics
3. Pulmonary Embolism Market Trends And Strategies
4. Pulmonary Embolism Market - Macro Economic Scenario
5. Pulmonary Embolism Market Size And Growth
…..
27. Pulmonary Embolism Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.